Replagal (Agalsidase Alfa) ( DrugBank: Agalsidase alfa )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
19	Lysosomal storage disease	3

19. Lysosomal storage disease

---

Clinical trials : 854 /  Drugs : 716 - (DrugBank : 105) / Drug target genes : 70 - Drug target pathways : 191

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01298141 (ClinicalTrials.gov)	August 10, 2011	15/2/2011	A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease	A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal® (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease	Fabry Disease	Biological: agalsidase alfa	Shire	NULL	Completed	N/A	N/A	All	171	Phase 3	Canada
2	NCT01363492 (ClinicalTrials.gov)	May 2011	31/3/2011	Safety Study of Replagal® Therapy in Children With Fabry Disease	An Open-Label Clinical Trial of Replagal® Enzyme Replacement Therapy in Children With Fabry Disease Who Are Naive to Enzyme Replacement Therapy	Fabry Disease	Biological: Replagal (agalsidase alfa)	Shire	NULL	Completed	7 Years	17 Years	All	15	Phase 2	United States
3	NCT00097890 (ClinicalTrials.gov)	November 2004	30/11/2004	Replagal Enzyme Replacement Therapy for Adults With Fabry Disease	An Open Label Six-Month Maintenance Clinical Trial of Replagal Enzyme Replacement Therapy in Patients With Fabry Disease Who Have Completed TKT027	Fabry Disease	Drug: Replagal (Agalsidase Alfa);Drug: Replagal	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	N/A	N/A	Male	25	Phase 4	United States